Cargando…
Muscle damage in patients with neuromyelitis optica spectrum disorder
OBJECTIVE: Increasing evidence has shown that skeletal muscle damage plays a role in neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to compare the serum creatine kinase (sCK) levels in NMOSD patients with different clinical statuses. METHODS: In the observational stu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608564/ https://www.ncbi.nlm.nih.gov/pubmed/28955716 http://dx.doi.org/10.1212/NXI.0000000000000400 |
_version_ | 1783265455694151680 |
---|---|
author | Chen, Hong-xi Zhang, Qin Lian, Zhi-yun Liu, Ju Shi, Zi-yan Miao, Xiao-hui Feng, Hui-ru Du, Qin Xie, Jing-lu Yao, Shao-li Zhou, Hong-yu |
author_facet | Chen, Hong-xi Zhang, Qin Lian, Zhi-yun Liu, Ju Shi, Zi-yan Miao, Xiao-hui Feng, Hui-ru Du, Qin Xie, Jing-lu Yao, Shao-li Zhou, Hong-yu |
author_sort | Chen, Hong-xi |
collection | PubMed |
description | OBJECTIVE: Increasing evidence has shown that skeletal muscle damage plays a role in neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to compare the serum creatine kinase (sCK) levels in NMOSD patients with different clinical statuses. METHODS: In the observational study, levels of sCK were measured during the acute and stable phases for patients with NMOSD and healthy controls (HCs). RESULTS: We enrolled 168 patients with NMOSD (female:male ratio, 153:15; age: 43.9 ± 13.1 years) in the acute phase, and blood samples were collected from 85 of the patients with NMOSD during both acute and stable phases to determine the sCK levels. The mean log sCK levels of the patients with NMOSD in the acute phase were higher (4.51 ± 1.17, n = 85) than those of the patients with NMOSD in the stable phase (3.85 ± 0.81, n = 85, p = 0.000). Furthermore, the log sCK levels of the patients with NMOSD in the stable phase were lower than those of the HCs (4.31 ± 0.39, n = 200, p = 0.000). In patients with sCK levels within the normal limits, these differences were also observed (p < 0.05). In the multivariable linear regression model performed for the patients with NMOSD in the acute phase, it suggested that a higher estimated glomerular filtration rate (p = 0.026), patients with the core clinical characteristics of optic neuritis (p = 0.005), and serum anti-SSA positivity (p = 0.019) predicted lower log sCK levels. CONCLUSIONS: Muscle damage occurs in patients with NMOSD and is aggravated during the acute phase. |
format | Online Article Text |
id | pubmed-5608564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-56085642017-09-27 Muscle damage in patients with neuromyelitis optica spectrum disorder Chen, Hong-xi Zhang, Qin Lian, Zhi-yun Liu, Ju Shi, Zi-yan Miao, Xiao-hui Feng, Hui-ru Du, Qin Xie, Jing-lu Yao, Shao-li Zhou, Hong-yu Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: Increasing evidence has shown that skeletal muscle damage plays a role in neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to compare the serum creatine kinase (sCK) levels in NMOSD patients with different clinical statuses. METHODS: In the observational study, levels of sCK were measured during the acute and stable phases for patients with NMOSD and healthy controls (HCs). RESULTS: We enrolled 168 patients with NMOSD (female:male ratio, 153:15; age: 43.9 ± 13.1 years) in the acute phase, and blood samples were collected from 85 of the patients with NMOSD during both acute and stable phases to determine the sCK levels. The mean log sCK levels of the patients with NMOSD in the acute phase were higher (4.51 ± 1.17, n = 85) than those of the patients with NMOSD in the stable phase (3.85 ± 0.81, n = 85, p = 0.000). Furthermore, the log sCK levels of the patients with NMOSD in the stable phase were lower than those of the HCs (4.31 ± 0.39, n = 200, p = 0.000). In patients with sCK levels within the normal limits, these differences were also observed (p < 0.05). In the multivariable linear regression model performed for the patients with NMOSD in the acute phase, it suggested that a higher estimated glomerular filtration rate (p = 0.026), patients with the core clinical characteristics of optic neuritis (p = 0.005), and serum anti-SSA positivity (p = 0.019) predicted lower log sCK levels. CONCLUSIONS: Muscle damage occurs in patients with NMOSD and is aggravated during the acute phase. Lippincott Williams & Wilkins 2017-09-13 /pmc/articles/PMC5608564/ /pubmed/28955716 http://dx.doi.org/10.1212/NXI.0000000000000400 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Chen, Hong-xi Zhang, Qin Lian, Zhi-yun Liu, Ju Shi, Zi-yan Miao, Xiao-hui Feng, Hui-ru Du, Qin Xie, Jing-lu Yao, Shao-li Zhou, Hong-yu Muscle damage in patients with neuromyelitis optica spectrum disorder |
title | Muscle damage in patients with neuromyelitis optica spectrum disorder |
title_full | Muscle damage in patients with neuromyelitis optica spectrum disorder |
title_fullStr | Muscle damage in patients with neuromyelitis optica spectrum disorder |
title_full_unstemmed | Muscle damage in patients with neuromyelitis optica spectrum disorder |
title_short | Muscle damage in patients with neuromyelitis optica spectrum disorder |
title_sort | muscle damage in patients with neuromyelitis optica spectrum disorder |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608564/ https://www.ncbi.nlm.nih.gov/pubmed/28955716 http://dx.doi.org/10.1212/NXI.0000000000000400 |
work_keys_str_mv | AT chenhongxi muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT zhangqin muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT lianzhiyun muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT liuju muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT shiziyan muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT miaoxiaohui muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT fenghuiru muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT duqin muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT xiejinglu muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT yaoshaoli muscledamageinpatientswithneuromyelitisopticaspectrumdisorder AT zhouhongyu muscledamageinpatientswithneuromyelitisopticaspectrumdisorder |